Ots1xbet.coma Pharmaceutical Co., Ltd.

• Establishment of the new company will further support Ots1xbet.coma's rapid growth in Europe which has been more than two-fold over the past 5 years.
• 1xbet.com European market comprises 25%^*of 1xbet.com total global pharmaceutical market making a strong European presence in clinical drug development essential.
• Ots1xbet.coma Europe Development and Commercialisation Ltd. is Ots1xbet.coma's 9th research and development institute.

(Tokyo, Japan and Uxbridge, 1xbet.com) Ots1xbet.coma Pharmaceutical Co., Ltd. (Ots1xbet.coma) today announced the formation of Ots1xbet.coma Europe Development and Commercialisation Ltd. (OEDC)

Established on July 1st, 2013, OEDC is an important milestone for Ots1xbet.coma's growing European pharmaceutical business and a significant long-term investment for Ots1xbet.coma in Europe. OEDC will be Ots1xbet.coma's European Research and Development Headquarters, working alongside Ots1xbet.coma Pharmaceutical Europe Ltd (OPEL) to ensure the successful development and commercialisation of our products.

"We are delighted to establish this new company in the 1xbet.com," said Dean Haubrich, President and CEO of OEDC. "We believe that Ots1xbet.coma has a great deal to contribute to the health and well-being of people in Europe and we look forward to reinforcing our strong, positive presence."

OEDC and OPEL are separate entities based in the same location, just outside London. This business model allows 1xbet.com optimal collaboration and is a critical success factor in the evolution of our global business. Our research and development and commercial operations teams will work closely together, with aligned goals, to build one fully integrated European company which will enable us to effectively respond to the increasingly rigorous regulatory environment.

"The opening of OEDC is a very important milestone for Ots1xbet.coma in Europe," said Ole Vahlgren, President and CEO of OPEL "This significant long-term investment will strengthen Ots1xbet.coma Europe's continued efforts to bring Ots1xbet.coma's innovative medicines to patients across Europe."

• * (C)2013 IMSHealth. Calculated based on IMS World Review 2013 (Executive Summary) Reprinted with permission

About Ots1xbet.coma Europe Development & Commercialisation Ltd.